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In the peripheral nervous system, utrophin and the short dystrophin isoform (Dp116) are co-
localized at the outermost layer of the myelin sheath of nerve fibers; together with the 
dystroglycan complex. Dp116 is associated with multiple glycoproteins, i.e. sarcoglycans, and α-
and β-dystroglycan, which anchor the cytoplasmic protein subcomplex to the extracellular basal 
lamina. In peripheral nerve, matrix metalloproteinase (MMP) activity disrupts the dystroglycan 
complex by cleaving the extracellular domain of β-dystroglycan. MMP creates a 30 kDa fragment 
of β-dystroglycan, leading to a disruption of the link between the extracellular matrix and the cell 
membrane. In this study, we investigated the molecular interactions of full length and 30 kDa β-
dystroglycan with Dp116 and utrophins in peripheral nerve Schwann cells from normal and mdx 
mice. Our results showed that Dp116 had greater affinity to the glycosylated form of β-
dystroglycan than the 30 kDa form. Interestingly, the short isoform of utrophin (Up71) was highly 
expressed in mdx Schwann cells compared with normal Schwann cells. In contrast to Dp116, 
Up71 had greater affinity to the 30 kDa β-dystroglycan. These results are discussed with regard 
to the participation of the short utrophin isoform and the cleaved form of β-dystroglycan in mdx 
Schwann cell membrane architecture and their possible role in peripheral nerve physiology. 
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Dystroglycan is encoded by a single gene and cleaved into two proteins by post-translational 
processing, resulting in an extracellular peripheral membrane glycoprotein, α-dystroglycan, and 
an integral membrane glycoprotein, β-dystroglycan (Ibraghimov-Beskrovnaya et al. 1992). In 
skeletal muscle, α-dystroglycan links laminin-2 and agrin in the basal lamina with α-dystroglycan 
in the sarcolemma (Ibraghimov-Beskrovnaya et al. 1992; Ervasti and Campbell 1993; Gee et al. 
1993; Fallon and Hall 1994). On the cytoplasmic side of the sarcolemma, β-dystroglycan (β-
DGfull: 43 kDa) is anchored to the cytoskeletal protein dystrophin (Jung et al. 1995). In addition, 
β-dystroglycan interacts with Grb2, an adaptor protein, and rapsyn, a peripheral protein required 
for acetylcholine receptor clustering, which suggests that the dystroglycan complex may also 
have signalling functions in skeletal muscle (Yang et al. 1995; Cartaud et al. 1998). The 
dystroglycan complex is also expressed in non-muscle tissues. In peripheral nerve, α- and β-
dystroglycans are expressed in the Schwann cell outer membrane apposing the endoneurial 
basal lamina but not in the inner membrane or compact myelin (Matsumura et al. 1993; Yamada 
et al. 1996). In the Schwann cell, α-dystroglycan links laminin-2 and agrin in the endoneurium 
with β-dystroglycan in the outer membrane (Feltri et al. 1999; Saito et al. 1999). Because 
peripheral myelination is greatly disturbed in congenital muscular dystrophy patients and dy mice 
deficient in laminin-2 (Matsumura et al. 1997), these findings suggest an involvement of the 
dystroglycan complex with laminin-2 in peripheral myelinogenesis (Masaki et al. 2002). 
Dysfunction of the dystroglycan complex has generally been implicated in the molecular 
pathogenesis of severe forms of hereditary neuromuscular diseases (Cohn et al. 2002; 
Matsumoto et al. 2005; Matsumura et al. 2005; Saito et al. 2005; van Reeuwijk et al. 2005). In 
this context, several studies have investigated proteolytic processing of the dystroglycan 
complex. A 30 kDa fragment of β-dystroglycan (β-DG30) was detected in normal peripheral 
nerve, kidney, lung, and smooth muscle, but not in skeletal muscle, cardiac muscle or brain 
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(Yamada et al. 2001; Zaccaria et al. 2001). This fragment is the product of proteolytic processing 
of the extracellular domain of β-dystroglycan by the membrane-associated matrix 
metalloproteinase (MMP) (Yamada et al. 2001). Processing disintegrates the dystroglycan 
complex and causes disruption of the link between the extracellular matrix (ECM) and the cell 
membrane, which could have profound effects on cell viability (Kaczmarek et al. 2002). 
The cytoskeletal protein dystrophin and its autosomal homologue utrophin are expressed in 
sarcolemma, where they serve as a link between the intracellular cytoskeleton and the 
extracellular matrix via the dystroglycan complex (Ibraghimov-Beskrovnaya et al. 1992; Ervasti 
and Campbell 1993). Both proteins have also been localized in nervous tissues such as 
peripheral nerve or brain (Love et al. 1993; Matsumura et al. 1993). Distal transcripts of the 
dystrophin gene have been identified and shown to be expressed differently from the full size 
427 kDa dystrophin. Dp116 is expressed in the Schwann cells of peripheral nerve (Byers et al. 
1993). Utrophin, a foetal homologue of dystrophin, is localized exclusively in the neuromuscular 
junction in adult skeletal muscle (Nguyen et al. 1991). Utrophin also has various transcripts, as 
previously described (Wilson et al. 1999). A short isoform with a molecular weight of 70 kDa 
(Up71) was detected in peripheral nerve (Fabbrizio et al. 1995; Rivier et al. 1996). Despite these 
discoveries, a number of questions remain concerning the implication of either the β-DG30 or the 
β-DGfull form in the anchorage of utrophin isoforms and Dp116 in Schwann cell membrane. We 
questioned whether these interactions were different in normal (C57BL/10) and dystrophin-
deficient mdx mouse Schwann cells. Dp116 and utrophin have a C-terminal domain containing 
the β-dystroglycan binding site (Byers et al. 1993; Matsumura et al. 1993). No studies have yet 
investigated the impact of β-dystroglycan processing on molecular interactions with full- and 
short-length utrophin. The short transcript Up71 is predicted to encode protein that has lost the 
N-terminal actin-binding domain and part of or the entire long spectrin like rod domain. Up71 
retains the C-terminal domains that mediate binding to β-DG. In this study we have 
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characterized the expression of Up71 isoform in peripheral nerve Schwann cells from normal 
and mdx mice. In addition we have investigated the effect of β-DGfull processing into β-DG30 by 
MMPs on molecular interaction with Dp116 and utrophin isoforms in normal and mdx Schwann 
cell membrane. 
 
EXPERIMENTAL PROCEDURES 
 
Animals and sciatic nerve dissection 
 
Six month-old control (C57BL/10) and mdx mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) and bred in our animal facilities. Mice were housed in plastic cages in a 
temperature-controlled environment with a 12-hour light/dark cycle and free access to food and 
water. The investigation conformed to the Guide for the Care and use of Laboratory animals 
published by the National institute of health (NIH). The animals were killed by rapid cervical 
dislocation. Animal experiments were carefully designed to minimize the number of animals and 
their suffering. Peripheral sciatic nerves (PN) were dissected and divided into two parts. One 
part was rapidly frozen in 2-methylbutane, cooled in liquid nitrogen and stored at -80°C until use 
for total protein extraction and immunohistochemical analysis. The second part was used as 
explants to make Schwann cell culture. 
 
Antibodies 
 
Polyclonal antibodies against β-dystroglycan (LG5), α-dysrobrevin1 (D124), α7B-integrin (K6) 
and dystrophin (H4) were produced and characterized, as previously described (Garcia-Tovar et 
al. 2002; Marquez et al. 2003; Royuela et al. 2003b). Polyclonal antibody against the utrophin C-
terminal end was produced as follows: utrophin C-terminal residues (3423-3433) was used as a 
specific antigenic sequence and the K7 antibody was obtained by injecting the KLH-linked 
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peptide as antigen, according to a previously described protocol (Royuela et al. 2003a). 
Monoclonal antibody (5A3) that recognized both dystrophin and utrophin was produced and 
characterized, as previously described (Fabbrizio et al. 1995; Rivier et al. 1996; Hernandez-
Gonzalez et al. 2005). Rabbit polyclonal antibody pan-Na+ and the Schwann cell marker S-100 
antibody were from Chemicon International. The monoclonal antibodies directed against 
dystrophin (DYS2), utrophin (DRP1), and β-dystroglycan (NCL-b-DG), were purchased from 
Novocastra. 
 
Histochemistry and immunofluorescence light microscopy 
 
Cryostat sections (transversal 10 μm) of unfixed and dissected PN (for Nodes of Ranvier and 
Schwann cell visualization) were double labelled with the polyclonal antibodies described above 
and S-100 or pan-Na+ antibodies. Immunoreactions were detected with Cy3- or FITC-conjugated 
sheep anti-rabbit IgG (Euromedex). All antibodies were tested in competition with corresponding 
synthetic peptides on cryostat sections. No immunofluorescence labelling was observed when 
peptides were applied. For negative controls only the second antibody was applied. Labelled 
sections were visualized under a Nikon optiphot-2 microscope and fluorescence intensity was 
analysed using Histolab program version 5-13-1 (Microvision Instrument, licence number; ).       
 
Total PN protein extraction and Western blotting 
 
First, 0.01 g of PN was homogenized in 150 μl of 5% SDS buffer (50 mM Tris/HCl, pH 8.0, 10 
mM EDTA, 5% SDS) supplemented with 1% trypsin inhibitor and 1% saponin. After 
centrifugation (10 min at 13,000 ×g), protein concentration was estimated in the supernatant 
using the BCA protein assay kit (Pierce). Then, 50 μl of SDS buffer containing 0.01% 
bromophenol blue, 10% glycerol and 5% β-mercaptoethanol was added to the supernatant and 
each sample was denatured for 5 min at 100°C. Protein extracts were submitted in duplicate to 
 7
SDS-PAGE (3-10% or 5-15%). The resulting gel was transferred onto 0.2 μm nitrocellulose 
membrane. Each blot was saturated in Tris-buffered saline with 0.1% Tween 20 (TBST) 
containing 3% bovine serum albumin (w/v). All membranes were incubated with primary 
antibodies for 1 h at room temperature. After labelling, the membranes were washed in TBST 
and then incubated with a phosphatase-labelled second antibody (Chemicon International). 
Antibody-bound proteins were detected with NBT/BCIP substrate, as previously described 
(Chazalette et al. 2005). 
Zymography 
 
Zymography was carried out according to Heussen and Dowdle (Heussen and Dowdle 1980). 
Zymogram gel (5-15% polyacrylamide) was impregnated with gelatin at 1mg/ml. After 
electrophoresis, the gel was washed in 2.5% Triton X100 solution at room temperature and 
incubated for 24 h in a substrate buffer (50mM Tris-Hcl, pH 8.0, 5mM CaCl2, 0.02% NaN3) at 
37°C. MMPs are secreted in a latent form and require cleavage of a peptide from their NH2 
terminus for activation. However, exposure of proenzymes of the tissue extracts to SDS during 
the gel separation procedure leads to activation without proteolytic cleavage. The gel was 
stained in Coomassie Blue R250 for 1 h and destained in water overnight. Gelatin-degrading 
enzymes were visualized as clear bands, indicating proteolysis of the substrate protein. Gel was 
treated in black/white colour and the MMP bands were quantified using the NIH image program. 
 
Schwann cell culture 
 
The nerve explants were sterilely divided into 1-mm segments and dissociated enzymatically 
using 0.05% collagenase (Sigma) and 0.1% hyaluronidase in 1 ml of F-12 solution (Gibco) at 
37°C for 2 h. The mixture was filtered through a 100-μm cell filter and centrifuged at 600 ×g for 5 
min. The supernatant was discarded and the pellet was suspended in Dulbecco’s Minimum 
Eagle’s Medium (DMEM; Gibco) containing 10% foetal bovine serum (FBS; Sigma), 2mM L-
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glutamine (Gibco), 1% streptavidin (Gibco), and 1% streptomycin (Gibco). The cell suspension 
was plated on a 75 cm2 flask (Nunc) and kept in a humidified atmosphere of 5% carbon dioxide 
at 37°C. Medium was replaced every 48 h. Isolation of Schwann cells was recorded according to 
a laminin-selection process recently described by Pannunzio et al. (Pannunzio et al. 2005). The 
primary culture was plated using laminin (Sigma) flasks coated immediately before use with 
5μg/ml laminin solution. After passages through the laminin-selection process, cells were 
maintained in culture until confluent with the previously described medium supplemented with 2 
μM forskolin (Sigma) to stimulate Schwann cell mitogenesis. The nature of the selected cells 
was determined visually based on cell morphology and Schwann cell marker S-100 by 
immunoflurescence. The homogeneity of the Schwann cells after five passages reached 80-
90%. 
 
Crude membrane fraction of PN Schwann cells 
 
Crude membrane fraction was prepared from 5 mg of Schwann cells homogenized in a Triton X-
100 lysis buffer (120 mM NaCl and 1% Triton X-100) supplemented with 10 mM iodoacetamid, 
1% saponin, 1% trypsin inhibitor, 20 mM PMSF and 1% leupeptin, as previously described 
(Yamada et al. 1996; Saito et al. 1999; Yamada et al. 2001). Homogenates were then 
centrifuged (140,000 ×g) for 30 min at 4°C and the supernatant was intensively washed and 
adjusted at the protein concentration of 5mg/ml in the lysis buffer for immunoprecipitation 
experiments. 
 
Enzymatic deglycosylation of the endogenous β-DGfull  
 
Neuraminidase (BioLabs) treatment was performed according to the protocol described by 
Yamada et al. (Yamada et al. 1996). Briefly, purified crude membrane was diluted in SDS 
solution and incubated at 100°C for 5 min. It was then diluted 10-fold with concentrated buffer 
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and distilled water to a final concentration of 0.5 M acetate buffer, pH 5.5, 1% Triton X-100, and 
1% SDS, and incubated with neuraminidase (10 mU/μg of substrate) at 37°C for 24 h. For 
control, samples were treated identically in the absence of neuraminidase. The deglycosylation 
reaction was stopped by adding SDS sample buffer to the incubation buffer and boiling at 100°C 
for 5 min. The neuroaminidase can also deglycosylates the α−dystroglycan but no direct action 
of MMPs on this glycoprotein has been reported previously. In our experiments we have not 
examined the impact of the processing on α-dystroglycan glycosylation.  
Limited proteolysis treatment with a specific protease solution (1mg/ml of fresh trypsin solution) 
of the protein Schwann cells homogenate containing Up395, Up71, and β-DG (43 and 30 kDa) 
was performed to test the behaviour of these proteins toward such conditions.  
 
Immunoprecipitation 
 
Immunoprecipitation was performed using 1) the supernatant containing the two isoforms of β-
DG and 2) the crude membrane fraction after enzymatic deglycosylation. The samples were 
incubated with the specific antibody (NCL-b-DG, DYS2, and DRP1) overnight at 4°C with gentle 
agitation. The protein-antibody complex was mixed with magnetic protein A micro-beads (MACS: 
Miltenyi Biotec). After extensive washing with a buffer containing 0.1% Triton X-100, 50 mM 
Tris/HCl, pH 8, 120 mM NaCl, 0.75 mM bezamedine and 0.1 mM PMSF, the magnetically 
labelled immune complex was purified over a micro-column placed in the magnetic field of the 
MACS separator. The bound fractions were eluted by a buffer containing 0.1% Triton X-100, 50 
mM Tris/HCl, pH 7.4, 0.35 Nacetyl-D-glucosamine, 0.75 mM bezamedine and 0.1 mM PMSF. 
Protein concentrations were estimated using the BCA protein assay (Pierce) to equilibrate 
samples. The experiments were performed in duplicate using total PN homogenate and 
Schwann cells crude membrane of C57BL/10 and mdx mice. 
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Blot overlay assay 
 
Proteins were separated by 5-15% SDS-PAGE and transferred to nitrocellulose membrane. The 
nitrocellulose transfers were blocked for 1 h at room temperature with 10 mM triethanolamine, 
pH 7.6, 140 mM NaCl, 1mM CaCl2, and 1mM MgCl2 containing 5% BSA (bovine serum 
albumin) and then incubated with the same solution containing 1mM dithiothreitol and the crude 
membrane cell homogenate overnight (O/N) at 4°C with gentle agitation (Imamura et al. 2000). 
After washing, the dystrophin and utrophin isoforms, which had bound to β-DG on the 
nitrocellulose transfers, were detected by C-ter dystrophin or C-ter utrophin antibodies. 
 
Semi-quantitative RT-PCR 
 
Total RNA was isolated from 108 Schwann cells with an SV total RNA isolation kit (Promega) 
following the manufacturer’s instructions. We used 0.1 μg of total RNA to generate first strand 
cDNA sequences with random hexanucleotide primers and the M-MLV reverse transcriptase 
(invitrogen). Of the RT reaction, 12 μl were subsequently used for each PCR reaction in 25 μl 
using the Taq Polymerase from Qbiogene. Three PCR reactions were performed to amplify the 
mouse Up395 isoform using the primers (mUp-ex17/20-F and mUp-ex17/20-F) previously 
described (Wilson et al. 1999). The mouse Up71 used a forward primer located in the unique 
first exon (FUP71, 5’-TTGAATACTGAGTAATAATTGAGTACTAG-3’), and a reverse primer 
located in exon 63 (RUp71, 5’-AAGAGCTCATTTTAGGATGAT-3’). The mouse β-DG gene 
fragment was amplified using the following primers: Fdag1-5’-GGAGGCTGTTCCCACCGTGGT-
3’; Rdag1, 5’-CTCTGCATTCTGTTCAACAGATCG-3’. The obtained PCR products were 383-pb 
(mUp395), 220-pb (mUp71) and 474-pb (dag1), respectively. The PCR conditions included 94°C 
for 5 min, 35 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 1 min, and a final extension of 72°C 
for 8 min. Assays was performed in duplicate and the different mRNA was expressed as a 
fraction of the House-keeping gene GAPDH which does not change between normal and mdx 
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Schwann cells. cDNA GAPDH amplification was used identically as the other PCR conditions to 
normalise expression level of Up395, Up71, and β-DG mRNA as described by Demestre et al. 
(Demestre et al.2004). Negative controls were performed, with total RNA replaced by either 
RNAase free water or reaction mixtures without RT (for DNA contamination). PCR products 
were visualized on 1.5% agarose gel. The 100-pb molecular mass markers (Promega) were 
used to estimate the molecular mass of the PCR products. 
 
Statistical analysis 
Immunolabeled sections were analyzed by Histolab program as described above. For each 
measure, images were taken under identical conditions and at the same objective. Data were 
averaged per dissected PN obtained from 3 C57BL/10 or mdx mice and statically compared 
using the man-Whitney test. Displayed data (mean ±S.D.) were normalized to the staining 
intensity of wild-type and comparisons were considered significant when *P<0.05. For 
Zymograhy and PCR band analysis scanned gels were treated in black/white colour and 
analysed by the NIH Image software package. Data were compared between normal and mdx 
mice using man-Whiney test as described above.      
 
RESULTS 
Peripheral nerve localization of Dp116, utrophin and associated proteins in C57BL/10 and 
mdx mice 
 
Immunofluorescence analysis of transversal cryostat sections of C57BL/10 and mdx nerve was 
performed using antibodies raised against Dp116, utrophin, and β-DG (Fig. 1). We observed 
identical labelling of the short dystrophin isoform (Dp116) in normal and dystrophin-deficient 
mice. The utrophin and β-DG staining was relatively higher in mdx PN sections (Fig. 1A and 1B). 
This result was confirmed by fluorescence intensity analysis of several sections of C57BL/10 
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and mdx peripheral nerve. Furthermore, using dissected PN to visualize nodes of Ranvier, 
Utrophin and β-DG labelling was stronger in several mdx nodes in comparison to C57BL/10 
nodes (Fig. 2A). This is approved by the comparative analysis of fluorescence intensity using 
several nodes of Ranvier (20 nodes) obtained from each mdx and C57BL/10 dissected PN (Fig. 
2B). Moreover, double labelling of Schwann cells with S-100 antibody and utrophin or β-DG 
antibodies showed also a high expression pattern of these tow proteins (Utrophin and β-DG) in 
the Schwann cells outer membrane of mdx nerve (Fig. 2C, 2D).  
 
Characterization of the short utrophin isoform Up71 in mdx mouse peripheral nerve 
 
In an attempt to establish a correlation between the intensive labelling of utrophin in the outer 
region of nerve fibres and its expression level, we analyzed total PN extracts of C57BL/10 and 
mdx mice (Fig. 3A). We detected a protein band with a Mr. 70 kDa of the utrophin family 
products, previously described by our team and others (Fabbrizio et al. 1993; Rivier et al. 1997; 
Wilson et al. 1999) in mdx PN extract by using three antibodies which recognize, respectively, 
both utrophin and dystrophin (Fig. 3A, panel a), only C-terminal dystrophin (Fig 3A, panel b) and 
only the C-terminal end of utrophin (Fig. 3A, panel c). We assumed that this protein was the 
short product Up71 of the utrophin gene (Wilson et al. 1999) because our antibody also 
recognized the same C-terminal sequence of the full-length utrophin (Up395). Western blot 
analysis revealed that Up71 was highly detected in mdx nerve. To further confirm our results, we 
performed semi-quantitative RT-PCR analyses of Up71, β-DG and Up395 mRNA in C57BL/10 
and mdx Schwann cells using specific primers for each transcript (Fig. 3B). When normalized to 
the GAPDH fraction Up71 mRNA level was strongly detected in mdx samples but weakly 
detected in C57BL10 samples. Up395 and β-DG had identical expression in normal and mdx 
samples. 
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Post-translational processing of β-DG in C57BL/10 and mdx nerve 
 
Western blot detection of β-DG and the other associated proteins in total PN extract showed that 
the two isoforms of this glycoprotein were present (Fig. 3C, panel a). It was reported that a 30 
kDa β-DG is detected in peripheral nerve extract and that this fragment is the product of 
proteolytic processing of the extracellular domain of the β-DGfull by matrix metalloproteinase 
(MMP) activity (Yamada et al. 2001). Our results confirmed this observation in both C57BL/10 
and mdx PN. Interestingly, the proteolytic processing in mdx PN seemed to be more highly 
activated, leading to a greater amount of the β-DG30, based on our Western blot detection (Fig. 
3C, panel a). In parallel, no difference was observed in the α-DB1 and α7B-integrin levels 
between C57BL/10 and mdx PN extracts (Fig 2C, panel b and c, respectively). 
 
MMP in normal and mdx PN 
 
Zymographic analysis of normal (C57BL/10) nerve extracts showed MMP-2 (major 60 kDa and 
minor 66 kDa latent forms), whereas both MMP-2 and a small amount of MMP-9 (100 kDa) were 
detected under the same non-reducing conditions in mdx nerve (Fig. 4A). MMP-2 and MMP-9 
were produced as zymogens in normal mouse peripheral nerves, with MMP-2 being the major 
form present in these nerves. It is constitutively produced by Schwann cells and neurons (Muir 
1995; Kherif et al. 1998). In an additional experiment we demonstrate that time course treatment 
with a protease solution (1 mg/ml trypsin) of Schwann cell homogenate containing Up395, Up71, 
and β-DG isoforms fail to produce any utrophin product with Mr. corresponding to Up71 or β-DG 
product with a Mr. of 30 kDa detectable by the corresponding antibodies in both C57BL/10 and 
mdx homogenate (Fig. 4B). To confirm the specific action of MMPs on β-DGfull into processing β-
DG30, Scwann cell was treated for 3 days by the MMPs inhibitor, N-biphenyl sulfonyl-
phenylalanine hydroxiamic acid (BPHA) (Maekawa et al. 1999), as described by Yamada et al. 
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(Yamada et al. 2001). Cells were harvested and analysed by western blot using β-DG C-ter 
antibody (Fig. 4C).     
 
Peripheral nerve β-DGfull and β-DG30 form two complexes that respectively anchor the 
Dp116 and utrophin isoforms 
 
All proteins detected in the peripheral nerve membrane were located along the outer membrane 
of the Schwann cells. To further investigate whether Up71 interacts with the transmembrane β-
DG, we analyzed the mdx Schwann cell crude membrane preparation by immunoprecipitation. 
Using the monoclonal β-DG antibody, utrophin and Up71 were immunoprecipitated from the 
crude membrane fraction in both normal and mdx Schwann cells and PN homogenate (Fig. 5A). 
In accordance with the Western blot results, the amount of precipitated Up71 relative to Up395 
was higher in the mdx fraction than in the normal C57BL/10 fraction (Fig. 5A, panel i). In both 
normal and mdx fraction, Dp116 was immunoprecipitated in equal amounts (Fig 5A, panel ii). 
Like Dp116, utrophin and the predicted sequence of Up71 had the same dystroglycan-binding 
site and were shown to bind to the same region of the β-DG cytoplasmic domain (Wilson et al. 
1999). This suggests that these proteins bind to β-DG in a competitive manner. 
Immunoprecipitation using the anti-Dp116 antibody (DYS2) coimmunoprecipitated β-DGfull and 
β-DG30 in the Schwann cells of both C57BL/10 and mdx crude fraction membrane (Fig. 5B, 
panel i). On the other hand, with immunoprecipitation assay using the C-ter utrophin antibody 
(DRP1), we detected more β-DG30 in the mdx fractions (Fig 5B, panel ii). This result is in 
agreement with previous reports which suggested that the interaction of utrophin with β-DGfull is 
weaker than that of Dp116 (Imamura et al. 2000). Another finding was that utrophin isoforms 
have more affinity to β-DG30, suggesting that processing of the β-DG may influence interactions 
between the other DAP complexes in Schwann cell membrane. 
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Effect of β-DG processing on Dp116 and utrophin isoform anchorage 
 
Purified crude fraction containing β-DG30 and β-DGfull in mdx Schwann cells was treated with 
neuraminidase to obtain the unique β-DG30 form (Fig. 6a). Dp116 and the utrophin isoforms 
were immunoprecipitated using the β-DG antibody (Fig. 6b and 6c, respectively). We observed 
that the immunoprecipitated Dp116 was more abundant in the untreated neuraminidase samples 
(Fig. 6b), whereas Up71 was abundantly immunoprecipitated in the treated samples (Fig. 6c). 
The utrophin full length Up395 was weakly immunoprecipitated in both treated and untreated 
samples (Fig. 6c). Dp116 seemed to have more affinity to β-DGfull, whereas β-DG30 anchored the 
utrophin isoforms (Up395 and Up71). This was more evident in mdx Schwann cells, depending 
on the relative abundance of the β-DG30 form, which resulted from the activation of the 
processing. To confirm this result, mdx Schwann cell crude membrane was separated on SDS-
PAGE, transferred to nitrocellulose membranes, and incubated with the elute fraction of the IP-β-
DG assay containing Dp116 and utrophin isoforms for overlay assay (Fig. 7a and 7b, 
respectively). After overlay, nitrocellulose membrane was revealed with dystrophin and utrophin 
antibodies, respectively. Dp116 seems to associate more with β-DGfull band (Fig. 7a), whereas 
the utrophin isoforms (especially Up71) have more affinity with β-DG30 band (Fig. 7b). 
DISCUSSION 
 
Taken together, the data presented here indicate two types of dystroglycan interaction in normal 
and mdx Schwann cells. The dystroglycan complex anchors Dp116, the short dystrophin 
isoform, and the utrophin isoforms. This interaction depends of the endogenous processing of β-
DG, the transmembrane glycoprotein, by matrix metallonoproteinases (MMPs) (Yamada et al. 
2001). MMPs have essentially two active forms (MMP-2 and MMP-9) and their activity is 
responsible for processing β-DGfull (43 kDa) into β-DG30 (30 kDa). The cleavage site was 
predicted to be in the extracellular domain of β-DG, and β-DG30 was predicted to be its C-
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terminal fragment. β-DG30 is increased in the skeletal and cardiac muscles of cardiomyopathic 
hamsters, the model animals of sarcoglycanopathy (SGCP), and in the skeletal muscle of DMD 
patients, but not in other muscular diseases (Matsumura et al. 2005). Here, we investigated the 
processing of β-DG in normal (C57BL/10) and mdx nerve and its impact on Dp116/utrophin 
anchorage in Schwann cell membrane. In normal nerves, MMP-2 was strongly detected while 
MMP-9 was weakly expressed. Both pro- and active forms of MMP-2 and MMP-9 are expressed 
in mdx muscle, whereas only MMP-2 is constitutive in normal muscle (Kherif et al. 1999). This 
agrees with the idea that the combined activity of MMP-2 and MMP-9 in mdx and DMD muscle 
extracts could explain the greater amount of β-DG30 in these extracts than in C57BL/10 extracts 
(Yamada et al. 2001; Roma et al. 2004). MMP-9 is activated in crushed nerve and in mdx 
muscle (Kherif et al. 1998; Kherif et al. 1999). As MMP-9 can degrade myelin basic protein 
(Yang and Bryant 1994; Platt et al. 2003), an increase in proteolytic activity due to the release of 
MMP-9 by macrophages may enhance myelin degradation (Kieseier et al. 1999). Proteolysis 
may also be required to free Schwann cells from their basement membrane connection as they 
proliferate and to re-establish axonal connections (Ferguson and Muir 2000). This finding leads 
us to suggest that the greater amount of β-DG30 observed in mdx PN extract was probably due 
to an extrinsic activation of MMP-9 by infiltrating macrophages within the mdx dystrophic muscle 
(Kherif et al. 1999). In fact, it was shown that in mdx muscle MMP-9 expression is related to the 
inflammatory response and probably to the activation of satellite cells, whereas MMP-2 
activation is concomitant with the regeneration of new myofibers (Barani et al. 2003). In our 
experiments, we showed that mdx nerve expresses more MMP-9 than normal nerve and such 
activation correlates with the increased level of β-DG30. In a second part of the experiment, we 
investigated the expression of Dp116 and utrophin comparatively in mdx and normal PN. 
Western blot analysis revealed that the utrophin short isoform (Up71) was detected in mdx 
extracts. We characterized this isoform by RT-PCR analysis and Western blot detection using a 
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C-terminal antibody directed against the last ten amino acids of the utrophin sequence. Several 
groups have observed small gene products using antibodies raised against the utrophin C-
terminus (Fabbrizio et al. 1995; Rivier et al. 1996). Up71 is a short transcript of utrophin with a 
unique first exon located in intron 62 and predicted to encode a 4.0 kb mRNA and a 71 kDa 
protein with the same cysteine-rich and C-terminal domains as full-length utrophin, commencing 
with exon 63 (dystrophin exon numbering) (Wilson et al. 1999). These domains are implicated in 
interactions with β-DG (Tinsley et al. 1992). Like full-length utrophin, the Up71 isoform is 
ubiquitously expressed and was detected by our team and others in the peripheral nervous 
system and the small peripheral arteries (Fabbrizio et al. 1995; Rivier et al. 1996, 1997; Wilson 
et al. 1999). To date there has been little information about the expression of this short transcript 
and its implication in DMD pathology. We demonstrate here that Up71 expression is increased in 
mdx nerve. Immunoprecipitation and blot overlay assay showed that Up71 has more affinity to β-
DG30 than the full-length isoform Up395, while Dp116 interacts with β-DGfull in both C57BL/10 
and mdx Schwann cell membrane. This result agrees with the findings of Imamura et al., who 
suggested that the interaction of Up395 with β-DGfull is weaker than that of Dp116 (Imamura et 
al. 2000). In agreement with previous reports, we showed that β-DGfull and β-DG30 have identical 
extraction profiles (Yamada et al. 2001). They were both extracted by 2% Triton X-100 and high 
ionic strength enhanced the effect of the detergent. Because β-DG is a type I integral membrane 
protein with a single transmembrane domain, these results indicate that β-DG30 retains this 
transmembrane domain. This is further supported by the finding that β-DG30 is recognized by the 
C-terminal antibody of β-DGfull. What effects this processing have on DAP complex integrity in 
Schwann cell membrane? The finding that β-DG30 did not interact with α-dystroglycan, indicates 
that the cleavage of β-DGfull into β-DG30 disintegrates the dystroglycan complex. Because α- and 
β-DG are responsible for binding to the basement membranes, this cleavage will disrupt the link 
between the basement and Schwann cell membrane. Proteolysis mediated by MMPs may also 
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be required to free the Schwann cells from their basement membrane connection as they 
proliferate. This could explain why no pathological effect was noted in mdx nerve despite the 
constant MMP activation and β-DG30 accumulation. However, MMPs were active in mdx skeletal 
muscle and, during the degeneration-regeneration process; MMP-9 is essentially produced by 
both inflammatory and activated satellite cells (Guerin and Holland 1995). These cells produce 
MMP-9 in response to different stimuli from necrotic tissue and are an important source of MMP-
9. It is well established that macrophages from blood infiltrate the injured nerve and are 
responsible for clearing myelin and other debris (Kherif et al. 1998). We suggest that the 
spatially and temporally limited MMP-9 activity in mdx nerve is mediated by inflammatory and 
degenerative-regenerative processes in the microenvironment of necrotic mdx fibres. On the 
other hand, the increase in MMP-9 may help break down the blood-nerve barrier and thus 
facilitate macrophage infiltration. This activation is not sufficient to promote disruption of mdx 
nerve function. Our results suggest that β-DG processing is a constitutive process in normal and 
mdx nerves. The persistence and the high level of β-DG30 in mdx Schwann cell membrane could 
be explained by its specific anchorage to the short utrophin isoform Up71 which confer to β-DG30 
more stabilization in membrane. This could be an argument for a potential implication of these 
two proteins in the degenerative-regenerative process of mdx nerve (See the hypothetical model 
proposed in Fig. 8). This idea is all the more attractive because β-DG interacts with adaptor 
proteins like Grb2 and rapsyn, which are implicated in signalling cascades during nerve 
regeneration. Our data suggest a novel role for β-DG30 and the short utrophin transcript Up71 in 
the Schwann cell membrane and nerve physiology. 
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Figure Legends 
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Fig. 1. (A) Localization of DAP complex in normal (C57B/10) and mdx transversal peripheral 
nerve sections. Dp116 (A1, A2) and utrophin (UTR) (A3, A4) were detected in Schwann cell 
outer membrane as shown by the S-100 antibody (A5, A6) which labels myelinated and non-
myelinated Schwann cells. (B) β-dystroglycan (β-DG) (B1, B2), α-dystrobrevin1 (α-DB1) (B3, 
B4), and α7B-integrin (α7B-ITG) (B5, B6) detection on transversal PN section in C57BL/10 and 
mdx nerve showed different localization of these proteins in nerve. β-DG which showed the most 
intensive labelling and α-DB1 were localized in the in Schwann cell outer membrane whereas 
α7B-ITG is expressed in axon region. Bar = 15 μm.  
 
Fig. 2. (A) Localization of Dp116 (A1, A2), Utrophin (UTR) (A5, A6) and β-dystroglycan (β-DG) 
(A9, A10) in nodes of Ranvier. A3, A7, A11 showed the specific labelling of Nodes of Ranvier 
(arrows) with the pan-Na+ antibody and the Hematoxylin/eosin (H&E) staining (A4, A8, and A12). 
Dp116 seems deceased in some nodes of Ranvier in mdx sections (A2), whereas utrophin and 
β-DG (A6 and A10 respectively) were highly detected compared with C57BL/10 (A5 and A9). (B) 
Immunolabelling of utrophin (UTR) (B1, B3) and β-dystroglycan (β-DG) (B5, B7) in the outer 
membrane of Schwann cells on isolated C57BL/10 and mdx nerve fibres. The same Schwann 
cells (Arrow head) were also detected by the S-100 antibody (B2, B6 and B4, B8) 5µm.      
 
Fig. 3. (A) Immunodetection of DAP complex in C57BL/10 and mdx peripheral nerve extracts. a) 
Western blots revealed a dystrophin isoform (Dp116) and utrophin isoforms (Up395 and Up71) 
in C57BL/10 and mdx total nerve extracts, using a monoclonal antibody recognizing both 
dystrophin and utrophin (5A3). b) Dp116 detection on the same extracts with C-terminal 
dystrophin antibody (H4). c) C-ter utrophin antibody (K7) detection showed the full utrophin 
(Up395) in C57BL/10 and both Up395 and the short product Up71 (71 kDa) in mdx extract. d) 
Represents Western blot detection of β-dystroglycan (β-DG) in C57BL/10 and mdx nerve 
 28
extracts. We noted that two isoforms of β-DG (43 kDa and 30 kDa) were present in PN extracts 
the 43 kDa isoform (β-DGfull) was more abundant in C57BL/10 extract than in mdx one. In the 
opposite, the 30 kDa (β-DG30) was more represented in mdx PN extract than in normal one. All 
the samples were equilibrated according to β-actin detection. (B) Semi-quantitative RT-PCR 
analysis of a) Up395, b) β-DG and c) Up71 transcripts. PCR products after cDNA amplification of 
Up71, Up395 and β-DG of C57BL/10 and mdx Schwann cells nerves. Assay was performed in 
duplicate and the different mRNA was expressed as a fraction of the House-keeping gene 
GAPDH. The 100-pb molecular mass markers (Promega) were used to estimate the molecular 
mass of the PCR products. d) Statistical analysis of the mRNA level of the Up395, β-GD and 
Up71. Black histograms correspond to mdx samples whereas the white histograms represents 
that of wild-type (C75BL/10) samples.    
 
Fig. 4. (A) Zymographic analysis of normal (C57BL/10) and mdx nerve. In normal nerve extract, 
both MMP-2 (major 60 kDa and minor 66 kDa latent forms) and MMP-9 (100 kDa) were detected 
under non-reducing conditions. In mdx extracts, both gelatinases were also expressed with a 
significant difference in the intensity of the MMP-9 band, which was more expressed compared 
with C57BL/10 extract. Histograms under the gels represent statistical analysis of the gelatinase 
bands in the two samples. Experiments were performed in triplicate and statistical significance 
(*) was set at P < 0.05. Data are expressed as mean ± SEM. (B) Limited proteolysis (0-35 
second) with a fresh trypsin solution (1mg/ml, final concentration of 1%) showed disappearance 
of the endogenous Up395, Up71, and the two isoforms of β-DG (β-DGfull and β-DG30) in 
C57BL/10 (a) or mdx  (b) and Schwann cell homogenates when detected with the C-ter utrophin 
antibody (left panels) or with C-ter β-DG antibody (right panel). Suppression of β-DGfull into β-
DG30 was performed by MMP inhibitor (BPHA). Mdx Schwann cells were treated with 0.5μg/ml 
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or 20μg/ml BPHA and after 3 days cells were analysed by immunoblotting using β-DG C-ter 
antibody.   
 
Fig.5. Co-mmunoprecipitation of β-dystroglycan, Dp116 and utrophin isoforms in Schwann cell 
membrane (SC) and total PN homogenate (PN). (A) Each membrane fraction of the normal and 
mdx Schwann cell and PN in both C57BL/10 and mdx mice was used for immunoprecipitation 
(IP) with a monoclonal antibody against β-DG (IP- β-DG). The protein composition of each 
precipitate was identified by immunoblotting with i) utrophin antibody and ii) dystrophin antibody. 
(iii) western blot of the endogenous β-DG in C57BL/10 and mdx homogenates. (B) The same 
membrane fractions were used for immunoprecipitation with i) monoclonal antibody against 
dystrophin (IP-DYS) and ii) utrophin (IP-UTR). Each precipitate was analyzed by immunoblotting 
using β-DG antibody that recognizes the two isoforms of β-DG (β-DGfull and β-DG30) identically in 
Schwann cells crude membrane and PN homogenate (Not shown). 
 
Fig.6. Effect of neuraminidase treatment on the binding of Dp116 and utrophin isoforms to mdx 
peripheral nerve β-dystroglycan. a) Membrane fractions of mdx Schwann cells were incubated 
with or without neuraminidase (+ and -, respectively) and separated by 5-15% SDS-PAGE, 
transferred to nitrocellulose membrane and then revealed with β-DG antibody. After 
neuraminidase treatment, only the 30 kDa form of β-DG (β-DG30) was present in the membrane 
fraction. Untreated and treated samples were used for immunoprecipitation with β-DG antibody 
(panel b and c). The untreated neuraminidase fraction contained both isoforms of β-DG (Neur–), 
while the treated fraction contained only the 30 kDa β-DG (Neur+). Each precipitate was 
electroblotted and reveled with C-terminal dystrophin (panel b) and C-terminal utrophin (panel c) 
antibodies. 
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Fig.7. Blot overlay analysis of the binding of Dp116 and utrophin isoforms with the Schwann cell 
membrane protein fraction of mdx mouse. Mdx Schwann cell membrane was separated by 5-
15% SDS-PAGE, transferred to nitrocellulose membrane, and overlaid O/N at 4°C with the 
crude membrane fraction after β-DG immunoprecipitation (IP- β-DG) (see Fig. 5). After intensive 
washing, the nitrocellulose membrane was revealed by the dystrophin antibody (panel a) and 
the utrophin antibody (panel b). In panel a, the arrows show positive bands with an Mr. of 117 
kDa (corresponding to the Dp116 band) and an intensive 49 kDa band revealed with dystrophin 
antibody that corresponds to the Dp116 fraction associated with the 43 kDa β-DG after overlay. 
Panel b shows the nitrocellulose membrane revealed by utrophin antibody after overlay. Three 
bands were detected (70 kDa, 49 kDa and 30 kDa). The 70 kDa band corresponds to Up71, the 
second band corresponds to the amount of utrophin fraction which bound the β-DGfull, and the 
last band (most intensive) corresponds to the utrophin fraction which bound to β-DG30. Panel c 
represents the Western blot revelation of β-DG, utrophin, and dystrophin before overlay. 
 
Fig.8. Hypothetical model of β-BG-Dp116, -Up395 and -Up71 interaction in C57BL/10 and mdx 
peripheral nerve. a) β-BG is localized in the Schwann cell outer membrane, whereas Dp116 and 
Up395 are localized in the Schwann cell cytoplasm. b) Normal (C57BL/10) and mdx Schwann 
cell membrane. The processing of β-BGfull to β-BG30 by MMPs (MMP-2 and MMP-9) leads to the 
disruption of the link between the basal lamina and the outer membrane. The Up71 anchorage 
to β-BG30 could stabilize this isoform in Schwann cell membrane to avoid any dysfunction in mdx 
nerve physiology.    
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